Tab. 1

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **WORK** | **PERIOD** | **POPULATION (Conversion Surgery)** | **MEDIAN - AGE** | **UNRESECTABLE CRITERIA** | **CHEMOTHERAPY** | **SURGERY** | **LYMPHADENECTOMY (D2 or more)** | **RO** |
| **P1** | **H1** | **Cy1** | **PAN/N3** | **T4** | **Other** |
| **Nakajima et al 1997 [73]** | 1989-1995 | 30 (19) | 53 | 9 (30%) | 11 (37%) |  | 23 (77%) | 8 (27%) | 3 (10%) | FLEP | n/s | n/s | 9 (30%) |
| **Yano et al 2002 [74]** | May1994-Dec1999 | 34 (14) | 54,4 (31-73) | 26 (76%) | 4 (12%) |  | 10 (3,4%) | 12 (35%) | 1 (0,3%) | FEMTXP or THP-FLPM | n/s | n/s | 8 (24%) |
| **Satoh et al 2012 [75]** | May2003-Mar2008 | 51 (44) | 63 (35-79) | 24 (49%) | 3 (6%) | 12 (23%) | 7 (14%) |  | 5 (10%) | S1 + Cisplatin | TG (58%) DG (21,5%) | 82% | 26 (51%) |
| **Kanda et al 2012 [76]** | Apr2000-Mar2008 | 31(28) | 65,5 (49-79) | 7 (25%) | 4 (14,3) |  | 15 (54%) | 9 (32%) |  | S1 + Cisplatin or Paclitaxel or Irinotecan | TG (42,89) DG (57,1%) | 96,30% | 26 (93%) |
| **Han et al 2014 [77]** | Jan2000-Dec2009 | 34 (34) | 56 (28-71) | 7 (14%) | 5 (10%) |  | 15 (29,4%) |  | 7 (14%) | 5-FU+Platinum or 5-FU+Platinum+Taxane | n/s | n/s | 26 (76,5%) |
| **Kim et al 2014 [78]** | Jan2003-Dec2012 | 43 (18) | 52,8 (32-72) | 43 (100%) |  |  |  |  |  | 5-FU+Cisplatin or S1+Cisplatin | TG (72,2%) DG (27,7%) | 100% | 10 (55%) |
| **Fukuchi et al 2015 [79]** | Feb2003-Dec2013 | 151 (40) | 66 (31-79) | 11 (28%) | 5 (13%) | 3 (8%) |  | 6 (15%) | 26 (65%) | S1 + Cisplatin or S1 + Paclitaxel | TG (72,5%) DG (27,5%) | n/s | 32 (80%) |
| **Kinoshita et al 2015 [80]** | Apr2006-Mar2012 | 57 (34) | 65 (30-78) | 15 (26%9 | 18 (32%) |  | 23 (40%) |  | 2 (3,5%) | DCS | TG (64,7%) DG (26,5%) | 50% | 27 (79%) |
| **Sato et al 2017 [81]** | Dec2002-Apr2014 | 100 (33) | 63 (26-78) | 33 (33%) | 29 (29%) |  | 61 (61%) | 14 (14%) | 11 (11%) | DCS I line, CPT-11 II line | TG (84,8%) DG (12,1%) | 100% | 28 (85%) |
| **Einama et al 2017 [82]** | Jan2009-Dec2015 | 10 | 70,5 (59-86) | 3 (30%) | 1 (10%) | 1 (10%) | 4 (40%) | 1 (10%) |  | S1 + CDDP or DOC | TG (40%) DG (30%) | 100% | 10 (100%) |
| **Mieno et al 2017 [83]** | Oct2006-Dec2012 | 31 (31) | 63 (35-78) | 25% | 16% |  | 58% | 26% |  | DCS + DS (Docetaxel-S1) in responder patients | TG (74,2%) DG (22,6%) | 77% | 23 (74%) |
| **Yamaguchi et al 2017 [84]** | 2001-2013 | 259 (84) | 61,7 (21-78) | 35 (41%) |  |  | 37 (44%) |  | 34 (40%) | DCS or S1 or S1+Cisplatin or S1+Taxane | TG (82,1%) DG (17,9%) | n/s | 43 (51%) |
| **Morgagni et al 2018 [85]** | Apr2005-Aug2016 | 73 (22) | 69 (59-74) |  |  |  |  |  |  | Epirubicin+Cisplatinum+5FU or Oxaliplatin + 5FU or Docetaxel+Oxaliplatin+5FU or Other | TG (72,7%) DG (22,7%) | 91,90% | 22 (100%) |
| P1: peritoneal carcinomatosis; H1: hepatic metastases; Cy1: positive cytology; PAN: para-aortic node metastases; TG: Total Gastrectomy; DG: Distal Gastrectomy; DCS/DS: Docetaxel-Cisplatin-S1/Docetaxel-Cisplatin; FEMTXP (fluorouracil, epirubicin, methotrexate, cisplatin); THP-FLPM: pirarubicin, 5-FU, Leucovorin, Cisplatin, mitomycin C; FLEP: 5-FU+Leucovorin+Etoposide; CDDP: cisplatin; DOC: docetaxel n/s: not specified |

Tab.2

|  |  |  |  |
| --- | --- | --- | --- |
| **WORK** | **yrs** | **OS (rate)** | **MST (months)** |
| **CHT** | **CHT+SURGERY** | **CHT** | **CHT+SURGERY** |
|  | **R1/R2** | **R0** |  | **R1/R2** | **R0** |
| **Nakajima et al 1997 [73]** | 2/3-yrs |  |  |  | 4.7 | 6.5 |  |
| 5-yrs |  |  | 55.6 |
| **Yano et al 2002 + [74]**  | 2/3-yrs |  |  |  |  |  |  |
| 5-yrs |  |  |  |
| **Satoh et al 2012 [75]** | 2/3-yrs |  | 43 | 75\* |  |  | 19.2 |
| 5-yrs |  |  |  |
| **Kanda et al 2012 [76]** | 2/3-yrs |  | 0 | 45.9 |  |  | 29 |
| 5-yrs |  |  | 34.4 |
| **Han et al 2014 [77]** | 2/3-yrs |  |  | 41.4 |  | 7.8 | 22.9 |
| 5-yrs |  |  |  |
| **Kim et al 2014 [78]** | 2/3-yrs | 0 | 0 | 50 | 8 | 18 | 37 |
| 5-yrs |  |  |  |
| **Fukuchi et al 2015 [79]** | 2/3-yrs |  |  |  | 14 | 30 | 62 |
| 5-yrs | 1 | 15 | 49 |
| **Kinoshita et al 2015 [80]** | 2/3-yrs | 0 | 16 | 63.5 | 9.6 | 29.9 |  |
| 5-yrs |  |  |  |
| **Sato et al 2017 [81]** | 2/3-yrs | 18.7 |  |  | 15.7 | 21.7 | 47.9 |
| 5-yrs | 0 | 0 | 48.6 |
| **Einama et al 2017 [82]** | 2/3-yrs |  |  |  |  |  | 29 |
| 5-yrs |  |  |  |
| **Mieno et al 2017 [83]** | 2/3-yrs | 56.9 |  | 73.1 |  | 56.1 |  |
| 5-yrs |  |  |  |
| **Yamaguchi et al 2017 [84]** | 2/3-yrs |  |  |  | 11,3 | 21.2 | 41.3 |
| 5-yrs |  |  |  |
| **Morgagni et al 2018 [85]** | 2/3 yrs | 0 |  | 39.4 | 14 |  | 38^^ |
| 5 yrs |  |  |  |
| OS: overall survival; MST: median survival time; CHT: chemotherapy; \*R0 in only pre-Cy1 patients ; + no data are specified but a p value < 0.0003 is shown between resected and not-resected 5-yrs OS rate; ^^ patients who had cytoreductive surgery plus HIPEC had an MST of 50 mts  |